{"gene":"FGF19","run_date":"2026-06-09T23:54:43","timeline":{"discoveries":[{"year":2007,"finding":"FGF19 requires β-Klotho (KLB) as a co-receptor to bind FGFR4 and signal in hepatocytes; tissue-specific co-expression of KLB with particular FGFR isoforms (especially FGFR4 in liver) determines the tissue-specific metabolic activities of FGF19. Both FGF19 and FGF21 can signal through FGFR1-3 bound by β-Klotho, but only FGF19 signals efficiently through FGFR4.","method":"Cell-based signaling assays, receptor binding studies, mouse in vivo injection experiments, gene expression analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — replicated across two independent papers (PMID 17623664 and 17627937) using multiple orthogonal methods including in vitro signaling, in vivo tissue-specific gene induction, and receptor co-expression analysis","pmids":["17623664","17627937"],"is_preprint":false},{"year":2007,"finding":"KLB is required for FGF19 binding to FGFR4, intracellular signaling, and downstream modulation of gene expression in hepatocytes. In mice, FGF19 injection triggers liver-specific induction of c-Fos and repression of CYP7A1 only where both KLB and FGFR4 are co-expressed.","method":"In vivo mouse injection, gene expression analysis, receptor distribution mapping","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — definitive in vivo evidence with tissue-specific readouts, replicated across labs","pmids":["17627937"],"is_preprint":false},{"year":2009,"finding":"FGF19 can interact directly with FGFR4 in the absence of β-Klotho in a heparin-dependent manner, whereas activation of FGFRs 1c, 2c, or 3c is completely β-Klotho-dependent. An FGF19 C-terminal deletion mutant (FGF19dCTD) lacking the β-Klotho interaction domain selectively activates FGFR4 signaling in liver and suppresses CYP7A1 but fails to improve glucose homeostasis in ob/ob mice, implicating adipose FGFR signaling (via β-Klotho) in glucose regulation.","method":"Receptor binding assays, engineered FGF19 deletion mutant (FGF19dCTD), in vivo mouse treatment, gene expression analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Moderate — structure-function mutagenesis with in vivo validation, single lab but multiple orthogonal approaches","pmids":["19706524"],"is_preprint":false},{"year":2009,"finding":"FGF19-induced hepatocyte proliferation is mediated specifically through FGFR4 activation. Amino acid residues 38–42 of FGF19 are sufficient to confer both FGFR4 activation and increased hepatocyte proliferation; an FGF19/FGF21 chimera carrying these residues gains hepatocyte mitogenic activity.","method":"C-terminal truncation mutants, FGF19/FGF21 chimeric molecules, in vivo hepatocyte proliferation assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — structure-function mapping by mutagenesis and chimeric proteins with in vivo validation, single lab with multiple orthogonal methods","pmids":["20018895"],"is_preprint":false},{"year":2010,"finding":"FGF19 structural determinants governing FGFR4 interaction (mitogenic) are separable from those governing FGFR1c/2c/3c interaction (metabolic). FGF19 variants that lose FGFR4 activation retain metabolic activity (glucose lowering, insulin sensitivity) but lose hepatocyte proliferative activity in mice.","method":"Structure-guided mutagenesis of FGF19, in vivo metabolic and proliferation assays in mice","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Moderate — structure-function dissection with in vivo metabolic and mitogenic readouts, multiple orthogonal methods in one rigorous study","pmids":["20660733"],"is_preprint":false},{"year":2011,"finding":"FGF19 stimulates hepatic protein synthesis and glycogen synthesis through a MAPK signaling pathway that activates components of the protein translation machinery and stimulates glycogen synthase activity, independently of insulin and Akt. Mice lacking FGF15 (mouse ortholog) fail to maintain postprandial blood glucose and liver glycogen; FGF19 treatment restored glycogen in insulin-deficient diabetic animals.","method":"In vivo isotope labeling for protein/glycogen synthesis, signaling pathway inhibitors, FGF15 knockout mice, streptozotocin-diabetic mouse model","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal in vivo and in vitro methods, genetic loss-of-function, and pharmacologic rescue across multiple models","pmids":["21436455"],"is_preprint":false},{"year":2011,"finding":"FGF19 regulates bile acid biosynthesis (CYP7A1 suppression) and hepatocyte proliferation via FGFR4, but FGFR4 is not essential for FGF19 to improve glucose and lipid metabolism; an FGF19 variant (FGF19v) selectively impaired in FGFR4 activation retains metabolic activity in high-fat diet and ob/ob mice.","method":"Fgfr4-deficient mice, FGF19v variant protein, in vivo metabolic phenotyping, gene expression","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic knockout combined with engineered protein variant, multiple in vivo readouts","pmids":["21437243"],"is_preprint":false},{"year":2011,"finding":"Pregnane X receptor (PXR) activation drives colon tumor growth via tumor-specific induction of FGF19; PXR binds the FGF19 promoter in colon cancer cells and induces FGF19 transcription only in cancer (not normal) cells, and PXR-mediated tumor phenotypes (growth, invasion, metastasis) require FGF19 signaling.","method":"Xenograft tumor model, ChIP assay (PXR binding to FGF19 promoter), RNAi knockdown, reporter assay","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus functional xenograft rescue, but single lab","pmids":["21747170"],"is_preprint":false},{"year":2012,"finding":"FGF21 binds FGFR1-KLB with much higher affinity than FGFR4-KLB, whereas FGF19 binds both FGFR1-KLB and FGFR4-KLB with comparable affinity. KLB is an indispensable mediator for FGF19 and FGF21 binding to FGFRs; FGF1 binds FGFRs independently of KLB and cannot displace FGF19/FGF21, and vice versa.","method":"Quantitative binding kinetics assays, downstream signal transduction assays, in vivo early response gene measurements in mice","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — quantitative binding kinetics with in vivo corroboration, single lab","pmids":["22442730"],"is_preprint":false},{"year":2012,"finding":"A biased FGF19 variant (FGF19-7) with strong preference for FGFR1c over FGFR4 is equally efficacious as wild-type FGF19 in regulating glucose, lipid, and energy metabolism in DIO and ob/ob mice, demonstrating that the βKlotho/FGFR1c receptor complex is central to the metabolic functions of endocrine FGFs.","method":"Engineered FGF19 receptor-specificity variant, in vivo metabolic phenotyping in multiple mouse models","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — structure-function with in vivo metabolic outcomes, single lab","pmids":["22457778"],"is_preprint":false},{"year":2014,"finding":"FGF19 promotes hepatocellular carcinoma (HCC) by activating the STAT3 pathway, an activity separable from its bile acid regulatory activity. An engineered FGF19 variant (M70) fully retains bile acid regulatory activity but does not activate STAT3 and does not promote HCC formation in mice; M70 also inhibits FGF19-dependent tumor growth.","method":"Engineered FGF19 variant (M70), transgenic mouse HCC model, STAT3 signaling assays, in vivo tumor growth assays","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — structure-function engineering with mechanistic pathway identification and in vivo tumor model, multiple orthogonal methods","pmids":["24728076"],"is_preprint":false},{"year":2017,"finding":"FGF19-driven hepatocarcinogenesis operates through a non-cell-autonomous mechanism: FGF19 stimulates IL-6 production in the liver microenvironment, which then activates STAT3 in hepatocytes. Hepatocyte-specific Stat3 deletion, Il6 ablation, anti-IL-6 antibody, or JAK inhibitor each abolish FGF19-induced tumorigenesis while leaving bile acid, glucose, and energy metabolic functions intact.","method":"Hepatocyte-specific Stat3 knockout, Il6 knockout mice, neutralizing anti-IL-6 antibody, JAK inhibitor, FGF19 transgenic mouse HCC model","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic and pharmacologic loss-of-function approaches in a defined in vivo tumor model, replicated through orthogonal approaches","pmids":["28508871"],"is_preprint":false},{"year":2017,"finding":"The pharmacologic weight-loss and glycemic effects of FGF19 (and FGF21) are mediated through the nervous system via β-Klotho in neurons, not via liver or adipose tissue. Neuronal-specific β-Klotho knockout abolishes FGF19-induced weight loss and glucose/insulin lowering, demonstrating the central nervous system as the primary mediator of these pharmacologic effects.","method":"Tissue-specific β-Klotho knockout mice (neuronal, hepatic, adipose), metabolic phenotyping","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — tissue-specific genetic loss-of-function with defined metabolic phenotypes, multiple tissue comparisons","pmids":["28988823"],"is_preprint":false},{"year":2017,"finding":"Postprandial FGF19 signaling activates Src kinase, which phosphorylates FXR at Y67 in hepatocytes. This phosphorylation is critical for FXR nuclear localization and transcriptional regulation of bile acid homeostasis. Liver-specific expression of phospho-defective Y67F-FXR or Src downregulation impairs homeostatic responses to bile acid feeding and exacerbates cholestatic pathologies.","method":"Phospho-site mutagenesis (Y67F-FXR), liver-specific viral expression, Src knockdown mice, bile acid feeding challenge, cholestatic drug model","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — phospho-site mutagenesis with in vivo loss-of-function and disease model validation, multiple orthogonal approaches","pmids":["29968724"],"is_preprint":false},{"year":2017,"finding":"FGF19 mediates postprandial epigenetic repression of hepatic autophagy through the FGF19-SHP-LSD1 axis: FGF19 signals to recruit Small Heterodimer Partner (SHP), which recruits histone demethylase LSD1 to CREB-bound autophagy gene promoters (including Tfeb), leading to demethylation of H3K4-me2/3 and repression of autophagy including lipophagy. FGF15-null mice show attenuated feeding-mediated autophagy inhibition.","method":"SHP-null mice, LSD1 knockdown mice, FGF15-null mice, ChIP assays, histone modification analysis, macroautophagy assays","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic models with ChIP mechanistic validation and defined epigenetic mechanism","pmids":["28446510"],"is_preprint":false},{"year":2015,"finding":"FGF19-stimulated SHP (Small Heterodimer Partner) is a global transcriptional partner of SREBP-2 in the liver. FGF19 increases functional interaction between endogenous SHP and SREBP-2, inhibiting SREBP-2 target genes involved in cholesterol biosynthesis. FGF19-induced phosphorylation of SHP at Thr-55 is required for its interaction with SREBP-2 and reduction of liver/serum cholesterol.","method":"Liver ChIP-seq (genome-wide SHP binding), Co-immunoprecipitation, SHP phospho-site mutagenesis, SHP-knockout mice, FGF19 treatment","journal":"Genome biology","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — ChIP-seq plus functional validation with phospho-mutagenesis and knockout models in single rigorous study","pmids":["26634251"],"is_preprint":false},{"year":2019,"finding":"FGF19/FGF15 signaling-activated Src phosphorylates hepatic FXR at Y67, which upregulates cholesterol transport genes (Scarb1, Abcg5/8) for biliary cholesterol excretion. Phospho-defective Y67F-FXR substitution blunts cholesterol-lowering, and Src knockdown impairs cholesterol regulation. FGF19 treatment increases FXR occupancy at Abcg5/8 and Scarb1 loci and promotes cholesterol efflux; these effects are abolished by Y67F-FXR or Src inhibition.","method":"Hepatic FXR knockout/knockdown reconstitution with Y67F mutant, Src knockdown, apoE-deficient atherosclerosis model, ChIP, cholesterol efflux assay, FGF19 treatment","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — phospho-mutagenesis, Src knockdown, multiple in vivo models, ChIP, functional efflux assays — multiple orthogonal methods","pmids":["30996006"],"is_preprint":false},{"year":2016,"finding":"FGF19 promotes epithelial-mesenchymal transition (EMT) in HCC cells via the FGFR4/GSK3β/β-catenin axis: FGF19 represses E-cadherin, and EMT induced by FGF19 is blocked by GSK3β inhibitor pretreatment or FGFR4 knockout, implicating GSK3β as a required intermediary.","method":"FGF19 overexpression/knockdown, FGFR4 CRISPR knockout, GSK3β inhibitor treatment, EMT marker analysis, invasion assays","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout plus pharmacologic inhibition with defined molecular readouts, single lab","pmids":["26498355"],"is_preprint":false},{"year":2017,"finding":"FGF19 protects HCC cells against endoplasmic reticulum stress-induced apoptosis through the FGFR4-GSK3β-Nrf2 signaling cascade, promoting nuclear accumulation of Nrf2. FGF19 expression in stressed cells is induced by ATF4, which directly binds the FGF19 promoter.","method":"ER stress induction in HCC cells, FGF19 overexpression/silencing, mouse xenograft model, signaling pathway analysis","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro mechanistic pathway dissection with in vivo xenograft validation, single lab","pmids":["28951455"],"is_preprint":false},{"year":2013,"finding":"ATF4 (activating transcription factor 4), activated in response to ER stress, directly binds an amino acid response element (AARE) in the FGF19 promoter and induces FGF19 transcription in intestinal cells independently of farnesoid X receptor. Thapsigargin-induced ER stress markedly increases FGF19 mRNA and secreted protein in Caco-2 cells; shRNA depletion of ATF4 attenuates this induction.","method":"Reporter gene assay with promoter deletion constructs, EMSA, ChIP assay, ATF4 overexpression/shRNA knockdown","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EMSA and ChIP with functional reporter and shRNA validation, single lab with multiple orthogonal methods","pmids":["23205607"],"is_preprint":false},{"year":2007,"finding":"FGF19 expression in intestinal cells is induced by lithocholic acid (LCA) via the pregnane X receptor (PXR). PXR/RXR overexpression with LCA or rifampicin stimulation drives FGF19 promoter activity, and the LCA-responsive element maps to a proximal region with two PXR binding half-sites.","method":"Reporter gene assay with FGF19 promoter deletion constructs, PXR/RXR co-transfection, qRT-PCR in LS174T intestinal cells","journal":"World journal of gastroenterology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter deletion mapping with PXR co-transfection, single lab, multiple constructs","pmids":["17696253"],"is_preprint":false},{"year":2012,"finding":"FXR transcriptionally activates FGF19 through multiple responsive elements in the FGF19 promoter and gene body (at -1866 to -1833, -1427 to -1353, and -75 to +262 relative to the transcription start), where FXR/RXRα heterodimers bind IR1, ER2, and DR8 motifs as confirmed by EMSA and ChIP assay.","method":"Reporter assay with multiple FGF19 promoter deletion constructs, EMSA, ChIP assay, mutagenesis of nuclear receptor binding motifs","journal":"The Journal of steroid biochemistry and molecular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EMSA, ChIP and functional mutagenesis, single lab with multiple orthogonal methods","pmids":["22561792"],"is_preprint":false},{"year":2013,"finding":"SREBP-2 negatively regulates FXR-dependent transcription of FGF19 in human intestinal cells by interacting directly with FXR and attenuating FXR/RXRα binding to the IR-1 motif in the FGF19 gene, without itself binding the IR-1 motif. GST pull-down confirmed direct SREBP-2/FXR protein interaction.","method":"Reporter gene assay, EMSA, ChIP assay, GST pull-down, overexpression of constitutively active SREBP-2, site mutagenesis","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — GST pull-down plus ChIP and reporter assays, single lab with multiple orthogonal methods","pmids":["24321096"],"is_preprint":false},{"year":2006,"finding":"FOXC1 transcription factor directly regulates FGF19 expression in corneal and periocular mesenchymal cells. FGF19 signals through FGFR4 tyrosine kinase to promote MAPK phosphorylation in the cornea. Loss of either FOXC1 or FGF19 causes complementary anterior segment dysgeneses.","method":"Chromatin enrichment assay, cell culture overexpression, zebrafish embryo loss-of-function, MAPK phosphorylation assays","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — chromatin binding assay, in vivo zebrafish loss-of-function, signaling readout — single lab","pmids":["17000708"],"is_preprint":false},{"year":2005,"finding":"In the chick embryo, FGF19 is expressed in the distal optic vesicle and signals through FGFR4 to participate in lens induction in collaboration with FGF8-L-Maf signaling. Inhibition of FGF19 signal via a secreted FGFR4 decoy induces L-Maf expression; L-Maf misexpression ectopically induces Fgf19; FGF8 induces Fgf19 in addition to L-Maf.","method":"Misexpression (gain-of-function) and secreted dominant-negative FGFR4 (loss-of-function) in chick embryo, gene expression analysis","journal":"Development, growth & differentiation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo gain- and loss-of-function in chick embryo with defined epistatic relationships, single lab","pmids":["15921496"],"is_preprint":false},{"year":2005,"finding":"In zebrafish, Fgf19 is required for forebrain development: Fgf19 knockdown reduces cell proliferation and survival in the embryonic brain, impairs development of the ventral telencephalon and diencephalon, and disrupts specification of GABAergic interneurons and oligodendrocytes. Fgf19 expression is downstream of Hedgehog (Hh) signaling, and Fgf19 overexpression partially rescues the forebrain phenotype caused by Hh inhibition.","method":"Morpholino knockdown of Fgf19 in zebrafish, Hh pathway inhibition, Fgf19 overexpression rescue experiment","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function morpholino and gain-of-function rescue in zebrafish with defined cellular phenotypes, single lab","pmids":["16256099"],"is_preprint":false},{"year":2007,"finding":"In zebrafish, Fgf19 expressed in the nasal retina and lens is required for lens fiber cell differentiation, cell survival (but not proliferation) in the lens and retina, and nasal-temporal patterning of the retina critical for retinal ganglion cell axon guidance. Loss of Fgf19 causes size reduction of lens and retina, failure of choroid fissure closure, and aberrant axon pathfinding.","method":"Morpholino knockdown of Fgf19, Fgf19 overexpression, eye transplantation in zebrafish, marker gene analysis","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function, gain-of-function, and tissue transplantation in zebrafish with defined developmental phenotypes","pmids":["18089288"],"is_preprint":false},{"year":2016,"finding":"In breast cancer cells co-expressing FGFR4 and FGF19, FGF19 acts as an autocrine ligand that activates FGFR4 to promote survival predominantly via PI3K/AKT signaling. siRNA silencing of FGF19 or neutralizing anti-FGF19 antibody decreases AKT phosphorylation and suppresses cancer cell growth and doxorubicin resistance specifically in FGFR4+/FGF19+ cells.","method":"siRNA knockdown, neutralizing antibody, AKT phosphorylation assays, cell viability assays in breast cancer cell lines","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNAi and antibody blockade with defined signaling readouts, single lab","pmids":["27192118"],"is_preprint":false},{"year":2018,"finding":"Molecular elements in the C-terminus of FGF19 are critical for KLB binding and receptor signaling. Short C-terminal FGF19 peptides competitively inhibit FGF19 activity via KLB binding. A single C-terminal amino acid in FGF19 modulates relative activity through FGFR1 versus FGFR4. The C-terminal sequence of FGF19 is structurally conserved for KLB binding despite sequence differences from FGF21.","method":"C-terminal peptide competition assays, alanine scanning mutagenesis, in vitro KLB-mediated signaling assays, in vivo obese mouse metabolic studies","journal":"Molecular metabolism","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — peptide-based structure-function with in vitro and in vivo validation, single lab","pmids":["29789271"],"is_preprint":false},{"year":2015,"finding":"IL-1β inhibits β-Klotho expression in hepatocytes via the JNK and NF-κB pathways, thereby impairing FGF19-induced ERK1/2 activation and cell proliferation. LPS inhibits β-Klotho and FGFR4 expression in mouse liver in vivo, but acts via IL-1β (not TNFα or IL-6) to inhibit β-Klotho transcription in liver cells.","method":"LPS treatment in vivo, cytokine treatment of hepatocyte cell lines, pathway inhibitors (JNK, NF-κB), FGF19 signaling readout (ERK1/2 phosphorylation), cell proliferation assay","journal":"American journal of physiology. Endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo and in vitro complementary approaches with defined signaling readouts, single lab","pmids":["26670488"],"is_preprint":false},{"year":2019,"finding":"FGF19 promotes HDL biogenesis and transhepatic cholesterol efflux by selectively modulating LXR signaling in the liver; ABCA1 and FGFR4 are identified as mediators. A constitutively active MEK1 (but not constitutively active STAT3) mimics FGF19/NGM282 effects on cholesterol, placing MEK1 downstream of FGF19 in cholesterol regulation.","method":"In vivo treatment of db/db and Apoe-/- mice, constitutively active MEK1/STAT3 constructs, ABCA1 and FGFR4 perturbation, cholesterol efflux assays, clinical trial measurement of HDL-C","journal":"Journal of lipid research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo mechanistic pathway dissection with constitutively active constructs and clinical corroboration, single lab","pmids":["30679232"],"is_preprint":false},{"year":2021,"finding":"FGF19/FGFR4 signaling promotes liver cancer stem cell (LCSC) self-renewal via activation of store-operated Ca2+ entry (SOCE) through both the PLCγ and ERK1/2 pathways. SOCE-calcineurin signaling then activates and induces nuclear translocation of NFATc2, which transcriptionally activates stemness genes (NANOG, OCT4, SOX2) as well as FGF19 itself, creating a positive feedback loop.","method":"FGF19 overexpression/silencing, FGFR4 activation/inhibition, Ca2+ imaging, sphere formation and clonogenicity assays, loss-of-function studies","journal":"Theranostics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple gain/loss-of-function approaches with defined Ca2+ signaling readouts, single lab","pmids":["33754043"],"is_preprint":false},{"year":2023,"finding":"FGF19/FGFR4 signaling elevates ETV4 expression through ERK1/2 in HCC cells; ETV4 in turn upregulates FGFR4, creating a positive feedback loop. ETV4 transactivates PD-L1 and CCL2, promoting TAM and MDSC infiltration and suppressing CD8+ T cells to facilitate HCC metastasis. CCR2 inhibition or CCL2 knockdown impairs ETV4-induced immune cell infiltration.","method":"Orthotopic HCC mouse models, lentiviral overexpression/knockdown, flow cytometry, immunofluorescence, clodronate liposome macrophage depletion, CCR2 inhibitor treatment","journal":"Journal of hepatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple in vivo models with immune cell phenotyping and pathway validation, single lab","pmids":["36907560"],"is_preprint":false},{"year":2023,"finding":"In colorectal cancer liver metastasis (CRLM), FGF19 induces polarization of hepatic stellate cells to inflammatory cancer-associated fibroblasts (iCAFs) by activating the FGFR4-JAK2-STAT3 pathway and an autocrine IL-1α loop. FGF19-induced iCAFs promote neutrophil extracellular trap (NET) formation via complement C5a and IL-1β, facilitating CRC liver colonization.","method":"In vivo liver metastasis models, FGFR4 pathway inhibition (fisogatinib), GPBAR1 knockout mice, GBC cell line experiments","journal":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo metastasis model with mechanistic pathway dissection, single lab","pmids":["37345586"],"is_preprint":false},{"year":2021,"finding":"In gallbladder carcinoma, bile acids upregulate FGF19 and FGFR4 co-expression by activating the GPBAR1-cAMP-EGR1 pathway. FGF19 secreted from GBC cells promotes GBC progression via autocrine FGFR4 activation and downstream ERK signaling.","method":"GBC cell line experiments, GPBAR1 knockout mice, human patient samples (serum/bile), FGFR4 inhibitor treatment, transcription factor analysis","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — complementary in vitro, in vivo, and human subject evidence for a defined signaling pathway, single lab","pmids":["34163030"],"is_preprint":false},{"year":2023,"finding":"HMGA1 chromatin regulator directly induces FGF19 expression by recruiting active histone marks (H3K4me3, H3K27Ac) to the FGF19 gene locus. FGF19 disruption (gene silencing or FGFR4 inhibitor BLU9931) recapitulates most phenotypes of HMGA1 deficiency — decreased tumor growth and desmoplastic stroma formation — in PDAC mouse models.","method":"RNA sequencing, ChIP for active histone marks, FGF19 gene silencing, FGFR4 inhibitor treatment, KPC mouse model, subcutaneous/orthotopic PDAC models","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-based epigenetic mechanism with multiple in vivo loss-of-function validation models, single lab","pmids":["36919699"],"is_preprint":false},{"year":2019,"finding":"The anti-obesity effect of FGF19 in mice does not require UCP1-dependent thermogenesis; FGF19-induced weight loss in UCP1 knockout mice is associated with inhibition of bile acid synthesis and reduction of dietary lipid absorption (increased fecal energy content, reduced hepatic bile acid species), rather than increased caloric expenditure.","method":"UCP1 knockout mice, FGF19 treatment, calorimetry, bile acid analysis, fecal energy content measurement, gene expression","journal":"Molecular metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout with pharmacologic treatment and multiple metabolic readouts, single lab","pmids":["31767164"],"is_preprint":false}],"current_model":"FGF19 is an ileum-derived postprandial endocrine hormone that acts as a ligand for receptor complexes comprising FGFR4 (primarily in liver) or FGFR1-3 (in adipose and other tissues) together with the obligate co-receptor β-Klotho (KLB); upon hepatic FGFR4/KLB activation it suppresses CYP7A1-mediated bile acid synthesis, stimulates insulin-independent glycogen and protein synthesis via a MAPK pathway, represses hepatic autophagy through an FGF19-SHP-LSD1 epigenetic axis, promotes cholesterol efflux via ABCA1/LXR/MEK1 signaling, and phosphorylates FXR at Y67 via Src to reinforce bile acid homeostasis; its mitogenic/oncogenic activity (hepatocellular carcinoma) is mediated separately through FGFR4-STAT3 activation driven non-cell-autonomously by IL-6 from the liver microenvironment, while its pharmacologic weight-loss and glycemic effects require neuronal β-Klotho independently of liver or adipose actions."},"narrative":{"mechanistic_narrative":"FGF19 is an intestine-derived endocrine hormone that coordinates postprandial hepatic metabolism by acting as a ligand for FGF receptors in partnership with the obligate co-receptor β-Klotho (KLB), with tissue-specific outputs dictated by which FGFR isoform is co-expressed with KLB [PMID:17623664, PMID:17627937]. Signaling efficiently through FGFR4-KLB in liver and through FGFR1c/2c/3c-KLB in extrahepatic tissues, FGF19 partitions its activities along structurally separable receptor-binding determinants: residues governing FGFR4 engagement drive bile acid suppression and hepatocyte proliferation, while distinct determinants mediate FGFR1c-dependent metabolic regulation of glucose and lipid homeostasis [PMID:19706524, PMID:20018895, PMID:20660733, PMID:22457778]. Through hepatic FGFR4 it represses CYP7A1-mediated bile acid synthesis [PMID:17627937], and it stimulates insulin-independent glycogen and protein synthesis via a MAPK pathway that activates glycogen synthase and the translation machinery [PMID:21436455]. FGF19 reinforces bile acid and cholesterol homeostasis by activating Src to phosphorylate FXR at Y67, controlling FXR nuclear localization and its transcription of cholesterol-transport genes [PMID:29968724, PMID:30996006], and it directs cholesterol handling through SHP—both as a phospho-dependent SREBP-2 partner suppressing cholesterol biosynthesis [PMID:26634251] and through an LXR/ABCA1/MEK1 axis promoting HDL biogenesis and cholesterol efflux [PMID:30679232]. FGF19 also enforces postprandial epigenetic repression of hepatic autophagy via an FGF19-SHP-LSD1 axis that demethylates H3K4 at autophagy gene promoters [PMID:28446510]. Its pharmacologic weight-loss and glycemic effects are mediated through neuronal β-Klotho rather than liver or adipose tissue [PMID:28988823], and anti-obesity action is independent of UCP1 thermogenesis, reflecting reduced bile acid synthesis and dietary lipid absorption [PMID:31767164]. Distinct from its metabolic roles, FGF19 is oncogenic in hepatocellular carcinoma through FGFR4-driven STAT3 activation that operates non-cell-autonomously via IL-6 from the liver microenvironment, an activity separable from bile acid regulation [PMID:24728076, PMID:28508871]. FGF19 transcription is induced in the intestine by bile acid/nuclear-receptor inputs (FXR, PXR) and by ER stress via ATF4 [PMID:23205607, PMID:17696253, PMID:22561792], and it functions developmentally through FGFR4-MAPK signaling in eye and forebrain morphogenesis [PMID:17000708, PMID:15921496, PMID:16256099, PMID:18089288].","teleology":[{"year":2007,"claim":"Established the receptor logic of FGF19 by showing that β-Klotho is the obligate co-receptor that licenses FGF19 binding and signaling, explaining how a circulating hormone achieves tissue-specific action.","evidence":"Cell-based signaling, receptor binding, and in vivo mouse injection with tissue-specific c-Fos/CYP7A1 readouts","pmids":["17623664","17627937"],"confidence":"High","gaps":["Structural basis of the FGF19-KLB-FGFR4 ternary complex not resolved","Determinants of FGFR isoform selectivity not yet mapped"]},{"year":2009,"claim":"Dissected which receptor drives which output, showing FGFR4 engagement is responsible for bile acid suppression and hepatocyte proliferation while β-Klotho/FGFR1c mediates glucose regulation.","evidence":"C-terminal deletion mutant (FGF19dCTD), chimeric FGF19/FGF21 proteins, in vivo treatment in ob/ob mice with gene expression and proliferation readouts","pmids":["19706524","20018895"],"confidence":"High","gaps":["Whether adipose versus other extrahepatic FGFR1c tissues carry the glucose effect not pinned down at this stage"]},{"year":2010,"claim":"Confirmed that mitogenic FGFR4 activity and metabolic activity are structurally separable, enabling design of non-mitogenic metabolic variants.","evidence":"Structure-guided mutagenesis with in vivo metabolic and proliferation assays in mice","pmids":["20660733"],"confidence":"High","gaps":["Long-term safety of FGFR4-sparing variants not addressed"]},{"year":2011,"claim":"Defined how FGF19 maintains postprandial fuel homeostasis, showing it drives glycogen and protein synthesis via MAPK independently of insulin/Akt.","evidence":"In vivo isotope labeling, pathway inhibitors, FGF15-null mice, and streptozotocin-diabetic rescue","pmids":["21436455","21437243"],"confidence":"High","gaps":["Receptor and effector linking MAPK to glycogen synthase not fully defined"]},{"year":2011,"claim":"Identified upstream transcriptional control of FGF19 by bile acids and xenobiotic sensing, including a pathological PXR-driven program in colon cancer.","evidence":"ChIP for PXR on FGF19 promoter, xenograft rescue, RNAi, and reporter assays; PXR/RXR LCA-responsive promoter mapping","pmids":["21747170","17696253"],"confidence":"Medium","gaps":["Single-lab xenograft evidence","Relevance of tumor-specific FGF19 induction to human colon cancer not established"]},{"year":2012,"claim":"Quantified FGF19 versus FGF21 receptor preferences and engineered biased variants, confirming the βKlotho/FGFR1c complex is central to metabolic action.","evidence":"Quantitative binding kinetics, signaling assays, and in vivo metabolic phenotyping of FGF19-7 variant in DIO/ob/ob mice","pmids":["22442730","22457778"],"confidence":"Medium","gaps":["Single-lab biased-variant data","Affinity measurements not tied to in-tissue receptor stoichiometry"]},{"year":2012,"claim":"Mapped the intestinal FXR-driven transcriptional activation of FGF19 and its negative regulation, defining feedback control of the bile acid circuit.","evidence":"Reporter assays, EMSA, ChIP, GST pull-down, and SREBP-2 overexpression in human intestinal cells","pmids":["22561792","24321096"],"confidence":"Medium","gaps":["In vivo relevance of SREBP-2/FXR antagonism not tested","Single-lab promoter work"]},{"year":2013,"claim":"Linked ER stress to FGF19 induction via ATF4 binding an amino acid response element in the promoter, independent of FXR.","evidence":"Reporter deletion constructs, EMSA, ChIP, and ATF4 overexpression/shRNA in Caco-2 cells","pmids":["23205607"],"confidence":"Medium","gaps":["Physiological/pathological context of stress-induced FGF19 not defined in vivo"]},{"year":2014,"claim":"Separated FGF19's oncogenic activity from its metabolic activity by showing HCC promotion proceeds through STAT3, an activity removable in the M70 variant.","evidence":"Engineered M70 variant, transgenic HCC mouse model, and STAT3 signaling/tumor growth assays","pmids":["24728076"],"confidence":"High","gaps":["Mechanism connecting FGFR4 to STAT3 not resolved at this stage"]},{"year":2015,"claim":"Identified SHP as a phospho-dependent SREBP-2 partner downstream of FGF19 that represses cholesterol biosynthesis genes genome-wide.","evidence":"Liver ChIP-seq, Co-IP, SHP Thr-55 phospho-mutagenesis, and SHP-knockout mice with FGF19 treatment","pmids":["26634251"],"confidence":"High","gaps":["Kinase phosphorylating SHP at Thr-55 not identified","Single rigorous study"]},{"year":2017,"claim":"Resolved the non-cell-autonomous basis of FGF19-driven HCC, showing FGF19 stimulates microenvironmental IL-6 that activates hepatocyte STAT3.","evidence":"Hepatocyte-specific Stat3 knockout, Il6 knockout, anti-IL-6 antibody, and JAK inhibitor in transgenic HCC mice","pmids":["28508871"],"confidence":"High","gaps":["Cellular source of IL-6 and the FGF19 receptor on those cells not fully defined"]},{"year":2017,"claim":"Localized the pharmacologic weight-loss and glycemic effects of FGF19 to neuronal β-Klotho, redefining the relevant target tissue.","evidence":"Neuronal, hepatic, and adipose tissue-specific β-Klotho knockout mice with metabolic phenotyping","pmids":["28988823"],"confidence":"High","gaps":["Specific neuronal populations and downstream circuits not identified"]},{"year":2017,"claim":"Defined a post-translational arm of bile acid homeostasis in which FGF19-activated Src phosphorylates FXR at Y67 to control its nuclear localization, and an epigenetic arm repressing hepatic autophagy via SHP-LSD1.","evidence":"Y67F-FXR phospho-mutagenesis, liver-specific viral expression, Src knockdown, bile acid feeding/cholestasis models; SHP-null, LSD1-knockdown, FGF15-null mice with ChIP and autophagy assays","pmids":["29968724","28446510"],"confidence":"High","gaps":["How FGF19/FGFR4 signaling activates Src not detailed","Promoter selectivity of the SHP-LSD1 complex incompletely defined"]},{"year":2019,"claim":"Extended FGF19's lipid control to biliary cholesterol excretion (via Y67-phosphorylated FXR at Abcg5/8 and Scarb1) and to HDL biogenesis through an LXR/ABCA1/MEK1 axis.","evidence":"Hepatic FXR reconstitution with Y67F mutant, Src knockdown, apoE-/- atherosclerosis model, ChIP, efflux assays; constitutively active MEK1/STAT3 constructs and ABCA1/FGFR4 perturbation in db/db and Apoe-/- mice","pmids":["30996006","30679232"],"confidence":"Medium","gaps":["Single-lab studies","Integration of MEK1 and FXR-phosphorylation arms not reconciled"]},{"year":2019,"claim":"Showed FGF19's anti-obesity action does not require UCP1 thermogenesis but reflects suppressed bile acid synthesis and reduced lipid absorption.","evidence":"UCP1 knockout mice with FGF19 treatment, calorimetry, bile acid and fecal energy analysis","pmids":["31767164"],"confidence":"Medium","gaps":["Reconciliation with the neuronal β-Klotho mechanism not directly addressed"]},{"year":2023,"claim":"Expanded the FGF19/FGFR4 oncogenic program across tumor types through autocrine signaling, feedback loops, and immune-stromal remodeling.","evidence":"Orthotopic/xenograft HCC, PDAC, gallbladder and colorectal liver metastasis models with pathway inhibitors, knockouts, ChIP, Ca2+ imaging, and immune cell phenotyping","pmids":["33754043","36907560","37345586","34163030","36919699","26498355","28951455","27192118"],"confidence":"Medium","gaps":["Each mechanism rests on single-lab evidence","Relative contribution of these parallel oncogenic arms in human tumors unclear"]},{"year":null,"claim":"How the divergent FGF19 outputs—hepatic metabolic, neuronal pharmacologic, and oncogenic STAT3/immune arms—are integrated at the level of receptor complex composition and downstream effector choice remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of context-dependent receptor complexes","Mechanism selecting MAPK versus STAT3 versus Src outputs not defined","Branch point between metabolic and oncogenic signaling not mapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,2,3,8]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,1,5]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[19]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[5,15,30]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,5,13]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[10,11]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[14]}],"complexes":[],"partners":["KLB","FGFR4","FGFR1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O95750","full_name":"Fibroblast growth factor 19","aliases":[],"length_aa":216,"mass_kda":24.0,"function":"Involved in the suppression of bile acid biosynthesis through down-regulation of CYP7A1 expression, following positive regulation of the JNK and ERK1/2 cascades. Stimulates glucose uptake in adipocytes. Activity requires the presence of KLB and FGFR4","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/O95750/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/FGF19","classification":"Not Classified","n_dependent_lines":28,"n_total_lines":1208,"dependency_fraction":0.023178807947019868},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/FGF19","total_profiled":1310},"omim":[{"mim_id":"620879","title":"FIBROBLAST GROWTH FACTOR-BINDING PROTEIN 3; FGFBP3","url":"https://www.omim.org/entry/620879"},{"mim_id":"617715","title":"MAM AND LDL RECEPTOR CLASS A DOMAIN-CONTAINING PROTEIN 1; MALRD1","url":"https://www.omim.org/entry/617715"},{"mim_id":"612084","title":"SOLUTE CARRIER FAMILY 51, SUBUNIT ALPHA; SLC51A","url":"https://www.omim.org/entry/612084"},{"mim_id":"611135","title":"KLOTHO, BETA; KLB","url":"https://www.omim.org/entry/611135"},{"mim_id":"609436","title":"FIBROBLAST GROWTH FACTOR 21; FGF21","url":"https://www.omim.org/entry/609436"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"gallbladder","ntpm":222.8}],"url":"https://www.proteinatlas.org/search/FGF19"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"O95750","domains":[{"cath_id":"2.80.10.50","chopping":"34-167","consensus_level":"high","plddt":92.1503,"start":34,"end":167}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O95750","model_url":"https://alphafold.ebi.ac.uk/files/AF-O95750-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O95750-F1-predicted_aligned_error_v6.png","plddt_mean":79.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FGF19","jax_strain_url":"https://www.jax.org/strain/search?query=FGF19"},"sequence":{"accession":"O95750","fasta_url":"https://rest.uniprot.org/uniprotkb/O95750.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O95750/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O95750"}},"corpus_meta":[{"pmid":"17623664","id":"PMC_17623664","title":"Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17623664","citation_count":651,"is_preprint":false},{"pmid":"21436455","id":"PMC_21436455","title":"FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis.","date":"2011","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/21436455","citation_count":515,"is_preprint":false},{"pmid":"21397858","id":"PMC_21397858","title":"Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening.","date":"2011","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/21397858","citation_count":373,"is_preprint":false},{"pmid":"24798001","id":"PMC_24798001","title":"Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification.","date":"2014","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/24798001","citation_count":342,"is_preprint":false},{"pmid":"17627937","id":"PMC_17627937","title":"Liver-specific activities of FGF19 require Klotho beta.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17627937","citation_count":236,"is_preprint":false},{"pmid":"28988823","id":"PMC_28988823","title":"FGF19, FGF21, and an FGFR1/β-Klotho-Activating Antibody Act on the Nervous System to Regulate Body Weight and Glycemia.","date":"2017","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/28988823","citation_count":226,"is_preprint":false},{"pmid":"17599042","id":"PMC_17599042","title":"Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models.","date":"2007","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/17599042","citation_count":223,"is_preprint":false},{"pmid":"24813368","id":"PMC_24813368","title":"Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients.","date":"2014","source":"International journal of obesity (2005)","url":"https://pubmed.ncbi.nlm.nih.gov/24813368","citation_count":177,"is_preprint":false},{"pmid":"29654817","id":"PMC_29654817","title":"Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis.","date":"2018","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/29654817","citation_count":176,"is_preprint":false},{"pmid":"36907560","id":"PMC_36907560","title":"FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2.","date":"2023","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/36907560","citation_count":175,"is_preprint":false},{"pmid":"24728076","id":"PMC_24728076","title":"Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19.","date":"2014","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/24728076","citation_count":159,"is_preprint":false},{"pmid":"21437243","id":"PMC_21437243","title":"FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21437243","citation_count":156,"is_preprint":false},{"pmid":"20018895","id":"PMC_20018895","title":"FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20018895","citation_count":156,"is_preprint":false},{"pmid":"17906623","id":"PMC_17906623","title":"Duplication of FGF3, FGF4, FGF19 and ORAOV1 causes hair ridge and predisposition to dermoid sinus in Ridgeback dogs.","date":"2007","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17906623","citation_count":156,"is_preprint":false},{"pmid":"22442730","id":"PMC_22442730","title":"Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22442730","citation_count":154,"is_preprint":false},{"pmid":"28069043","id":"PMC_28069043","title":"FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib.","date":"2017","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/28069043","citation_count":150,"is_preprint":false},{"pmid":"25080475","id":"PMC_25080475","title":"A nontumorigenic variant of FGF19 treats cholestatic liver diseases.","date":"2014","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25080475","citation_count":141,"is_preprint":false},{"pmid":"38001551","id":"PMC_38001551","title":"Gut microbiota-bile acid crosstalk regulates murine lipid metabolism via the intestinal FXR-FGF19 axis in diet-induced humanized dyslipidemia.","date":"2023","source":"Microbiome","url":"https://pubmed.ncbi.nlm.nih.gov/38001551","citation_count":132,"is_preprint":false},{"pmid":"31167419","id":"PMC_31167419","title":"FGF19-FGFR4 Signaling in Hepatocellular Carcinoma.","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/31167419","citation_count":127,"is_preprint":false},{"pmid":"20080590","id":"PMC_20080590","title":"Relevant use of Klotho in FGF19 subfamily signaling system in vivo.","date":"2010","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/20080590","citation_count":125,"is_preprint":false},{"pmid":"21747170","id":"PMC_21747170","title":"Pregnane X receptor activation induces FGF19-dependent tumor aggressiveness in humans and mice.","date":"2011","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/21747170","citation_count":122,"is_preprint":false},{"pmid":"29247039","id":"PMC_29247039","title":"H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma.","date":"2017","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/29247039","citation_count":118,"is_preprint":false},{"pmid":"12792807","id":"PMC_12792807","title":"Evolutionary conservation of CCND1-ORAOV1-FGF19-FGF4 locus from zebrafish to human.","date":"2003","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12792807","citation_count":116,"is_preprint":false},{"pmid":"15081372","id":"PMC_15081372","title":"Mouse FGF15 is the ortholog of human and chick FGF19, but is not uniquely required for otic induction.","date":"2004","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/15081372","citation_count":115,"is_preprint":false},{"pmid":"21813638","id":"PMC_21813638","title":"Roles of FGF19 in liver metabolism.","date":"2011","source":"Cold Spring Harbor symposia on quantitative biology","url":"https://pubmed.ncbi.nlm.nih.gov/21813638","citation_count":112,"is_preprint":false},{"pmid":"28508871","id":"PMC_28508871","title":"Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/28508871","citation_count":109,"is_preprint":false},{"pmid":"17878606","id":"PMC_17878606","title":"Actions and mode of actions of FGF19 subfamily members.","date":"2007","source":"Endocrine journal","url":"https://pubmed.ncbi.nlm.nih.gov/17878606","citation_count":104,"is_preprint":false},{"pmid":"22675463","id":"PMC_22675463","title":"Fundamentals of FGF19 & FGF21 action in vitro and in vivo.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22675463","citation_count":103,"is_preprint":false},{"pmid":"33751819","id":"PMC_33751819","title":"FGF19 protects skeletal muscle against obesity-induced muscle atrophy, metabolic derangement and abnormal irisin levels via the AMPK/SIRT-1/PGC-α pathway.","date":"2021","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33751819","citation_count":92,"is_preprint":false},{"pmid":"20660733","id":"PMC_20660733","title":"Separating mitogenic and metabolic activities of fibroblast growth factor 19 (FGF19).","date":"2010","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/20660733","citation_count":91,"is_preprint":false},{"pmid":"26498355","id":"PMC_26498355","title":"FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3β/β- catenin signaling cascade via FGFR4 activation.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26498355","citation_count":91,"is_preprint":false},{"pmid":"30089729","id":"PMC_30089729","title":"Divergent effects of resistance and endurance exercise on plasma bile acids, FGF19, and FGF21 in humans.","date":"2018","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/30089729","citation_count":90,"is_preprint":false},{"pmid":"24662279","id":"PMC_24662279","title":"Bile acid diarrhoea and FGF19: new views on diagnosis, pathogenesis and therapy.","date":"2014","source":"Nature reviews. Gastroenterology & hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/24662279","citation_count":88,"is_preprint":false},{"pmid":"28189755","id":"PMC_28189755","title":"Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15.","date":"2017","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/28189755","citation_count":85,"is_preprint":false},{"pmid":"37345586","id":"PMC_37345586","title":"FGF19-Induced Inflammatory CAF Promoted Neutrophil Extracellular Trap Formation in the Liver Metastasis of Colorectal Cancer.","date":"2023","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/37345586","citation_count":84,"is_preprint":false},{"pmid":"33414764","id":"PMC_33414764","title":"FGF19 and FGF21 for the Treatment of NASH-Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human.","date":"2020","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/33414764","citation_count":78,"is_preprint":false},{"pmid":"19706524","id":"PMC_19706524","title":"Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice.","date":"2009","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19706524","citation_count":78,"is_preprint":false},{"pmid":"32154250","id":"PMC_32154250","title":"Dissecting the Role of the FGF19-FGFR4 Signaling Pathway in Cancer Development and Progression.","date":"2020","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/32154250","citation_count":74,"is_preprint":false},{"pmid":"32794259","id":"PMC_32794259","title":"The Commensal Microbe Veillonella as a Marker for Response to an FGF19 Analog in NASH.","date":"2020","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/32794259","citation_count":74,"is_preprint":false},{"pmid":"22396170","id":"PMC_22396170","title":"FGF19 and cancer.","date":"2012","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/22396170","citation_count":73,"is_preprint":false},{"pmid":"28951455","id":"PMC_28951455","title":"FGF19 Protects Hepatocellular Carcinoma Cells against Endoplasmic Reticulum Stress via Activation of FGFR4-GSK3β-Nrf2 Signaling.","date":"2017","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/28951455","citation_count":73,"is_preprint":false},{"pmid":"27192118","id":"PMC_27192118","title":"Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27192118","citation_count":71,"is_preprint":false},{"pmid":"16256099","id":"PMC_16256099","title":"Fgf19 regulated by Hh signaling is required for zebrafish forebrain development.","date":"2005","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/16256099","citation_count":69,"is_preprint":false},{"pmid":"30518874","id":"PMC_30518874","title":"FGF19 amplification reveals an oncogenic dependency upon autocrine FGF19/FGFR4 signaling in head and neck squamous cell carcinoma.","date":"2018","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/30518874","citation_count":67,"is_preprint":false},{"pmid":"33383173","id":"PMC_33383173","title":"FGF19 and FGF21: In NASH we trust.","date":"2020","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/33383173","citation_count":66,"is_preprint":false},{"pmid":"31206730","id":"PMC_31206730","title":"Direct and Indirect Effects of Fibroblast Growth Factor (FGF) 15 and FGF19 on Liver Fibrosis Development.","date":"2019","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/31206730","citation_count":66,"is_preprint":false},{"pmid":"28446510","id":"PMC_28446510","title":"A postprandial FGF19-SHP-LSD1 regulatory axis mediates epigenetic repression of hepatic autophagy.","date":"2017","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/28446510","citation_count":65,"is_preprint":false},{"pmid":"28943626","id":"PMC_28943626","title":"Targeting FGF19/FGFR4 Pathway: A Novel Therapeutic Strategy for Hepatocellular Carcinoma.","date":"2015","source":"Diseases (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/28943626","citation_count":64,"is_preprint":false},{"pmid":"33288659","id":"PMC_33288659","title":"ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma.","date":"2020","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/33288659","citation_count":63,"is_preprint":false},{"pmid":"29968724","id":"PMC_29968724","title":"Postprandial FGF19-induced phosphorylation by Src is critical for FXR function in bile acid homeostasis.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29968724","citation_count":63,"is_preprint":false},{"pmid":"26856750","id":"PMC_26856750","title":"Characterizing Factors Associated With Differences in FGF19 Blood Levels and Synthesis in Patients With Primary Bile Acid Diarrhea.","date":"2016","source":"The American journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/26856750","citation_count":55,"is_preprint":false},{"pmid":"18089288","id":"PMC_18089288","title":"Fgf19 is required for zebrafish lens and retina development.","date":"2007","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/18089288","citation_count":53,"is_preprint":false},{"pmid":"34163030","id":"PMC_34163030","title":"FGF19 and FGFR4 promotes the progression of gallbladder carcinoma in an autocrine pathway dependent on GPBAR1-cAMP-EGR1 axis.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/34163030","citation_count":50,"is_preprint":false},{"pmid":"30074276","id":"PMC_30074276","title":"FGFR4 provides the conduit to facilitate FGF19 signaling in breast cancer progression.","date":"2018","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/30074276","citation_count":48,"is_preprint":false},{"pmid":"17696253","id":"PMC_17696253","title":"Lithocholic acid induction of the FGF19 promoter in intestinal cells is mediated by PXR.","date":"2007","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/17696253","citation_count":48,"is_preprint":false},{"pmid":"28570655","id":"PMC_28570655","title":"Circulating FGF19 closely correlates with bile acid synthesis and cholestasis in patients with primary biliary cirrhosis.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28570655","citation_count":48,"is_preprint":false},{"pmid":"31991869","id":"PMC_31991869","title":"Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31991869","citation_count":47,"is_preprint":false},{"pmid":"31201553","id":"PMC_31201553","title":"Pharmacologic Modulation of Bile Acid-FXR-FGF15/FGF19 Pathway for the Treatment of Nonalcoholic Steatohepatitis.","date":"2019","source":"Handbook of experimental pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31201553","citation_count":46,"is_preprint":false},{"pmid":"33249195","id":"PMC_33249195","title":"Small hepatitis B virus surface antigen promotes malignant progression of hepatocellular carcinoma via endoplasmic reticulum stress-induced FGF19/JAK2/STAT3 signaling.","date":"2020","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/33249195","citation_count":46,"is_preprint":false},{"pmid":"24393342","id":"PMC_24393342","title":"Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations.","date":"2014","source":"Liver international : official journal of the International Association for the Study of the Liver","url":"https://pubmed.ncbi.nlm.nih.gov/24393342","citation_count":45,"is_preprint":false},{"pmid":"37260446","id":"PMC_37260446","title":"Biological and pharmacological functions of the FGF19- and FGF21-coreceptor beta klotho.","date":"2023","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/37260446","citation_count":44,"is_preprint":false},{"pmid":"30464200","id":"PMC_30464200","title":"Suppression of Hepatic Bile Acid Synthesis by a non-tumorigenic FGF19 analogue Protects Mice from Fibrosis and Hepatocarcinogenesis.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30464200","citation_count":44,"is_preprint":false},{"pmid":"36919699","id":"PMC_36919699","title":"HMGA1 induces FGF19 to drive pancreatic carcinogenesis and stroma formation.","date":"2023","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/36919699","citation_count":43,"is_preprint":false},{"pmid":"25854696","id":"PMC_25854696","title":"FGF19 promotes progression of prostate cancer.","date":"2015","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/25854696","citation_count":43,"is_preprint":false},{"pmid":"30976983","id":"PMC_30976983","title":"Plasma FGF-19 Levels are Increased in Patients with Post-Bariatric Hypoglycemia.","date":"2019","source":"Obesity surgery","url":"https://pubmed.ncbi.nlm.nih.gov/30976983","citation_count":43,"is_preprint":false},{"pmid":"33389337","id":"PMC_33389337","title":"S100A16 promotes metastasis and progression of pancreatic cancer through FGF19-mediated AKT and ERK1/2 pathways.","date":"2021","source":"Cell biology and toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/33389337","citation_count":42,"is_preprint":false},{"pmid":"22457778","id":"PMC_22457778","title":"Characterization of a FGF19 variant with altered receptor specificity revealed a central role for FGFR1c in the regulation of glucose metabolism.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22457778","citation_count":40,"is_preprint":false},{"pmid":"29883717","id":"PMC_29883717","title":"Interaction of glucocorticoids with FXR/FGF19/FGF21-mediated ileum-liver crosstalk.","date":"2018","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/29883717","citation_count":39,"is_preprint":false},{"pmid":"29789271","id":"PMC_29789271","title":"Molecular elements in FGF19 and FGF21 defining KLB/FGFR activity and specificity.","date":"2018","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/29789271","citation_count":39,"is_preprint":false},{"pmid":"32003601","id":"PMC_32003601","title":"Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dysbiosis and hyperplasia in a novel pig model of pediatric NASH.","date":"2020","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/32003601","citation_count":39,"is_preprint":false},{"pmid":"33754043","id":"PMC_33754043","title":"FGF19/SOCE/NFATc2 signaling circuit facilitates the self-renewal of liver cancer stem cells.","date":"2021","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/33754043","citation_count":39,"is_preprint":false},{"pmid":"17000708","id":"PMC_17000708","title":"FGF19 is a target for FOXC1 regulation in ciliary body-derived cells.","date":"2006","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17000708","citation_count":39,"is_preprint":false},{"pmid":"26670488","id":"PMC_26670488","title":"IL-1β inhibits β-Klotho expression and FGF19 signaling in hepatocytes.","date":"2015","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/26670488","citation_count":38,"is_preprint":false},{"pmid":"30996006","id":"PMC_30996006","title":"Phosphorylation of hepatic farnesoid X receptor by FGF19 signaling-activated Src maintains cholesterol levels and protects from atherosclerosis.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30996006","citation_count":37,"is_preprint":false},{"pmid":"24465767","id":"PMC_24465767","title":"Soluble expression of disulfide bond containing proteins FGF15 and FGF19 in the cytoplasm of Escherichia coli.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24465767","citation_count":37,"is_preprint":false},{"pmid":"24297792","id":"PMC_24297792","title":"Carbohydrate feeding dissociates the postprandial FGF19 response from circulating bile acid levels in humans.","date":"2013","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/24297792","citation_count":37,"is_preprint":false},{"pmid":"27384874","id":"PMC_27384874","title":"Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27384874","citation_count":37,"is_preprint":false},{"pmid":"38212977","id":"PMC_38212977","title":"Targeting the FGF19-FGFR4 pathway for cholestatic, metabolic, and cancerous diseases.","date":"2024","source":"Journal of internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38212977","citation_count":36,"is_preprint":false},{"pmid":"36915160","id":"PMC_36915160","title":"FGF19 increases mitochondrial biogenesis and fusion in chondrocytes via the AMPKα-p38/MAPK pathway.","date":"2023","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/36915160","citation_count":36,"is_preprint":false},{"pmid":"30784284","id":"PMC_30784284","title":"LncRNA SNHG16 promotes cell proliferation through miR-302a-3p/FGF19 axis in hepatocellular carcinoma.","date":"2019","source":"Neoplasma","url":"https://pubmed.ncbi.nlm.nih.gov/30784284","citation_count":36,"is_preprint":false},{"pmid":"17654705","id":"PMC_17654705","title":"Expression of chick Fgf19 and mouse Fgf15 orthologs is regulated in the developing brain by Fgf8 and Shh.","date":"2007","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/17654705","citation_count":35,"is_preprint":false},{"pmid":"36692476","id":"PMC_36692476","title":"Serum FGF19 predicts outcomes of Kasai portoenterostomy in biliary atresia.","date":"2023","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/36692476","citation_count":34,"is_preprint":false},{"pmid":"28178326","id":"PMC_28178326","title":"Quantitative liver proteomics identifies FGF19 targets that couple metabolism and proliferation.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28178326","citation_count":34,"is_preprint":false},{"pmid":"36923538","id":"PMC_36923538","title":"FGF19-mediated ELF4 overexpression promotes colorectal cancer metastasis through transactivating FGFR4 and SRC.","date":"2023","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/36923538","citation_count":33,"is_preprint":false},{"pmid":"33674622","id":"PMC_33674622","title":"The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33674622","citation_count":33,"is_preprint":false},{"pmid":"26634251","id":"PMC_26634251","title":"Liver ChIP-seq analysis in FGF19-treated mice reveals SHP as a global transcriptional partner of SREBP-2.","date":"2015","source":"Genome biology","url":"https://pubmed.ncbi.nlm.nih.gov/26634251","citation_count":33,"is_preprint":false},{"pmid":"32111983","id":"PMC_32111983","title":"Enhanced autocrine FGF19/FGFR4 signaling drives the progression of lung squamous cell carcinoma, which responds to mTOR inhibitor AZD2104.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/32111983","citation_count":32,"is_preprint":false},{"pmid":"30679232","id":"PMC_30679232","title":"Therapeutic FGF19 promotes HDL biogenesis and transhepatic cholesterol efflux to prevent atherosclerosis.","date":"2019","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/30679232","citation_count":31,"is_preprint":false},{"pmid":"35116006","id":"PMC_35116006","title":"The Role of FGF19 and MALRD1 in Enterohepatic Bile Acid Signaling.","date":"2022","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/35116006","citation_count":30,"is_preprint":false},{"pmid":"30279125","id":"PMC_30279125","title":"IVACAFTOR restores FGF19 regulated bile acid homeostasis in cystic fibrosis patients with an S1251N or a G551D gating mutation.","date":"2018","source":"Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society","url":"https://pubmed.ncbi.nlm.nih.gov/30279125","citation_count":30,"is_preprint":false},{"pmid":"31767164","id":"PMC_31767164","title":"The anti-obesity effect of FGF19 does not require UCP1-dependent thermogenesis.","date":"2019","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/31767164","citation_count":29,"is_preprint":false},{"pmid":"22561792","id":"PMC_22561792","title":"Involvement of multiple elements in FXR-mediated transcriptional activation of FGF19.","date":"2012","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/22561792","citation_count":29,"is_preprint":false},{"pmid":"24321096","id":"PMC_24321096","title":"SREBP-2 negatively regulates FXR-dependent transcription of FGF19 in human intestinal cells.","date":"2013","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/24321096","citation_count":29,"is_preprint":false},{"pmid":"15921496","id":"PMC_15921496","title":"FGF19-FGFR4 signaling elaborates lens induction with the FGF8-L-Maf cascade in the chick embryo.","date":"2005","source":"Development, growth & differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/15921496","citation_count":27,"is_preprint":false},{"pmid":"15862633","id":"PMC_15862633","title":"Expression of Fgf19 in the developing chick eye.","date":"2005","source":"Brain research. Developmental brain research","url":"https://pubmed.ncbi.nlm.nih.gov/15862633","citation_count":27,"is_preprint":false},{"pmid":"37122899","id":"PMC_37122899","title":"Adipose-derived stem cell/FGF19-loaded microfluidic hydrogel microspheres for synergistic restoration of critical ischemic limb.","date":"2023","source":"Bioactive materials","url":"https://pubmed.ncbi.nlm.nih.gov/37122899","citation_count":25,"is_preprint":false},{"pmid":"33691750","id":"PMC_33691750","title":"FGF19/FGFR4 signaling axis confines and switches the role of melatonin in head and neck cancer metastasis.","date":"2021","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/33691750","citation_count":25,"is_preprint":false},{"pmid":"28906590","id":"PMC_28906590","title":"FGF19 genetic amplification as a potential therapeutic target in lung squamous cell carcinomas.","date":"2017","source":"Thoracic cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28906590","citation_count":25,"is_preprint":false},{"pmid":"28591793","id":"PMC_28591793","title":"Dynamics of Bile Acid Profiles, GLP-1, and FGF19 After Laparoscopic Gastric Banding.","date":"2017","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/28591793","citation_count":25,"is_preprint":false},{"pmid":"23205607","id":"PMC_23205607","title":"FGF19 (fibroblast growth factor 19) as a novel target gene for activating transcription factor 4 in response to endoplasmic reticulum stress.","date":"2013","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/23205607","citation_count":25,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53537,"output_tokens":9761,"usd":0.153513,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19875,"output_tokens":5158,"usd":0.114163,"stage2_stop_reason":"end_turn"},"total_usd":0.267676,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2007,\n      \"finding\": \"FGF19 requires β-Klotho (KLB) as a co-receptor to bind FGFR4 and signal in hepatocytes; tissue-specific co-expression of KLB with particular FGFR isoforms (especially FGFR4 in liver) determines the tissue-specific metabolic activities of FGF19. Both FGF19 and FGF21 can signal through FGFR1-3 bound by β-Klotho, but only FGF19 signals efficiently through FGFR4.\",\n      \"method\": \"Cell-based signaling assays, receptor binding studies, mouse in vivo injection experiments, gene expression analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — replicated across two independent papers (PMID 17623664 and 17627937) using multiple orthogonal methods including in vitro signaling, in vivo tissue-specific gene induction, and receptor co-expression analysis\",\n      \"pmids\": [\"17623664\", \"17627937\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"KLB is required for FGF19 binding to FGFR4, intracellular signaling, and downstream modulation of gene expression in hepatocytes. In mice, FGF19 injection triggers liver-specific induction of c-Fos and repression of CYP7A1 only where both KLB and FGFR4 are co-expressed.\",\n      \"method\": \"In vivo mouse injection, gene expression analysis, receptor distribution mapping\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — definitive in vivo evidence with tissue-specific readouts, replicated across labs\",\n      \"pmids\": [\"17627937\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"FGF19 can interact directly with FGFR4 in the absence of β-Klotho in a heparin-dependent manner, whereas activation of FGFRs 1c, 2c, or 3c is completely β-Klotho-dependent. An FGF19 C-terminal deletion mutant (FGF19dCTD) lacking the β-Klotho interaction domain selectively activates FGFR4 signaling in liver and suppresses CYP7A1 but fails to improve glucose homeostasis in ob/ob mice, implicating adipose FGFR signaling (via β-Klotho) in glucose regulation.\",\n      \"method\": \"Receptor binding assays, engineered FGF19 deletion mutant (FGF19dCTD), in vivo mouse treatment, gene expression analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — structure-function mutagenesis with in vivo validation, single lab but multiple orthogonal approaches\",\n      \"pmids\": [\"19706524\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"FGF19-induced hepatocyte proliferation is mediated specifically through FGFR4 activation. Amino acid residues 38–42 of FGF19 are sufficient to confer both FGFR4 activation and increased hepatocyte proliferation; an FGF19/FGF21 chimera carrying these residues gains hepatocyte mitogenic activity.\",\n      \"method\": \"C-terminal truncation mutants, FGF19/FGF21 chimeric molecules, in vivo hepatocyte proliferation assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — structure-function mapping by mutagenesis and chimeric proteins with in vivo validation, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"20018895\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"FGF19 structural determinants governing FGFR4 interaction (mitogenic) are separable from those governing FGFR1c/2c/3c interaction (metabolic). FGF19 variants that lose FGFR4 activation retain metabolic activity (glucose lowering, insulin sensitivity) but lose hepatocyte proliferative activity in mice.\",\n      \"method\": \"Structure-guided mutagenesis of FGF19, in vivo metabolic and proliferation assays in mice\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — structure-function dissection with in vivo metabolic and mitogenic readouts, multiple orthogonal methods in one rigorous study\",\n      \"pmids\": [\"20660733\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"FGF19 stimulates hepatic protein synthesis and glycogen synthesis through a MAPK signaling pathway that activates components of the protein translation machinery and stimulates glycogen synthase activity, independently of insulin and Akt. Mice lacking FGF15 (mouse ortholog) fail to maintain postprandial blood glucose and liver glycogen; FGF19 treatment restored glycogen in insulin-deficient diabetic animals.\",\n      \"method\": \"In vivo isotope labeling for protein/glycogen synthesis, signaling pathway inhibitors, FGF15 knockout mice, streptozotocin-diabetic mouse model\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal in vivo and in vitro methods, genetic loss-of-function, and pharmacologic rescue across multiple models\",\n      \"pmids\": [\"21436455\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"FGF19 regulates bile acid biosynthesis (CYP7A1 suppression) and hepatocyte proliferation via FGFR4, but FGFR4 is not essential for FGF19 to improve glucose and lipid metabolism; an FGF19 variant (FGF19v) selectively impaired in FGFR4 activation retains metabolic activity in high-fat diet and ob/ob mice.\",\n      \"method\": \"Fgfr4-deficient mice, FGF19v variant protein, in vivo metabolic phenotyping, gene expression\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout combined with engineered protein variant, multiple in vivo readouts\",\n      \"pmids\": [\"21437243\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Pregnane X receptor (PXR) activation drives colon tumor growth via tumor-specific induction of FGF19; PXR binds the FGF19 promoter in colon cancer cells and induces FGF19 transcription only in cancer (not normal) cells, and PXR-mediated tumor phenotypes (growth, invasion, metastasis) require FGF19 signaling.\",\n      \"method\": \"Xenograft tumor model, ChIP assay (PXR binding to FGF19 promoter), RNAi knockdown, reporter assay\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus functional xenograft rescue, but single lab\",\n      \"pmids\": [\"21747170\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"FGF21 binds FGFR1-KLB with much higher affinity than FGFR4-KLB, whereas FGF19 binds both FGFR1-KLB and FGFR4-KLB with comparable affinity. KLB is an indispensable mediator for FGF19 and FGF21 binding to FGFRs; FGF1 binds FGFRs independently of KLB and cannot displace FGF19/FGF21, and vice versa.\",\n      \"method\": \"Quantitative binding kinetics assays, downstream signal transduction assays, in vivo early response gene measurements in mice\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — quantitative binding kinetics with in vivo corroboration, single lab\",\n      \"pmids\": [\"22442730\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"A biased FGF19 variant (FGF19-7) with strong preference for FGFR1c over FGFR4 is equally efficacious as wild-type FGF19 in regulating glucose, lipid, and energy metabolism in DIO and ob/ob mice, demonstrating that the βKlotho/FGFR1c receptor complex is central to the metabolic functions of endocrine FGFs.\",\n      \"method\": \"Engineered FGF19 receptor-specificity variant, in vivo metabolic phenotyping in multiple mouse models\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — structure-function with in vivo metabolic outcomes, single lab\",\n      \"pmids\": [\"22457778\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"FGF19 promotes hepatocellular carcinoma (HCC) by activating the STAT3 pathway, an activity separable from its bile acid regulatory activity. An engineered FGF19 variant (M70) fully retains bile acid regulatory activity but does not activate STAT3 and does not promote HCC formation in mice; M70 also inhibits FGF19-dependent tumor growth.\",\n      \"method\": \"Engineered FGF19 variant (M70), transgenic mouse HCC model, STAT3 signaling assays, in vivo tumor growth assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — structure-function engineering with mechanistic pathway identification and in vivo tumor model, multiple orthogonal methods\",\n      \"pmids\": [\"24728076\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FGF19-driven hepatocarcinogenesis operates through a non-cell-autonomous mechanism: FGF19 stimulates IL-6 production in the liver microenvironment, which then activates STAT3 in hepatocytes. Hepatocyte-specific Stat3 deletion, Il6 ablation, anti-IL-6 antibody, or JAK inhibitor each abolish FGF19-induced tumorigenesis while leaving bile acid, glucose, and energy metabolic functions intact.\",\n      \"method\": \"Hepatocyte-specific Stat3 knockout, Il6 knockout mice, neutralizing anti-IL-6 antibody, JAK inhibitor, FGF19 transgenic mouse HCC model\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic and pharmacologic loss-of-function approaches in a defined in vivo tumor model, replicated through orthogonal approaches\",\n      \"pmids\": [\"28508871\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"The pharmacologic weight-loss and glycemic effects of FGF19 (and FGF21) are mediated through the nervous system via β-Klotho in neurons, not via liver or adipose tissue. Neuronal-specific β-Klotho knockout abolishes FGF19-induced weight loss and glucose/insulin lowering, demonstrating the central nervous system as the primary mediator of these pharmacologic effects.\",\n      \"method\": \"Tissue-specific β-Klotho knockout mice (neuronal, hepatic, adipose), metabolic phenotyping\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — tissue-specific genetic loss-of-function with defined metabolic phenotypes, multiple tissue comparisons\",\n      \"pmids\": [\"28988823\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Postprandial FGF19 signaling activates Src kinase, which phosphorylates FXR at Y67 in hepatocytes. This phosphorylation is critical for FXR nuclear localization and transcriptional regulation of bile acid homeostasis. Liver-specific expression of phospho-defective Y67F-FXR or Src downregulation impairs homeostatic responses to bile acid feeding and exacerbates cholestatic pathologies.\",\n      \"method\": \"Phospho-site mutagenesis (Y67F-FXR), liver-specific viral expression, Src knockdown mice, bile acid feeding challenge, cholestatic drug model\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — phospho-site mutagenesis with in vivo loss-of-function and disease model validation, multiple orthogonal approaches\",\n      \"pmids\": [\"29968724\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FGF19 mediates postprandial epigenetic repression of hepatic autophagy through the FGF19-SHP-LSD1 axis: FGF19 signals to recruit Small Heterodimer Partner (SHP), which recruits histone demethylase LSD1 to CREB-bound autophagy gene promoters (including Tfeb), leading to demethylation of H3K4-me2/3 and repression of autophagy including lipophagy. FGF15-null mice show attenuated feeding-mediated autophagy inhibition.\",\n      \"method\": \"SHP-null mice, LSD1 knockdown mice, FGF15-null mice, ChIP assays, histone modification analysis, macroautophagy assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic models with ChIP mechanistic validation and defined epigenetic mechanism\",\n      \"pmids\": [\"28446510\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"FGF19-stimulated SHP (Small Heterodimer Partner) is a global transcriptional partner of SREBP-2 in the liver. FGF19 increases functional interaction between endogenous SHP and SREBP-2, inhibiting SREBP-2 target genes involved in cholesterol biosynthesis. FGF19-induced phosphorylation of SHP at Thr-55 is required for its interaction with SREBP-2 and reduction of liver/serum cholesterol.\",\n      \"method\": \"Liver ChIP-seq (genome-wide SHP binding), Co-immunoprecipitation, SHP phospho-site mutagenesis, SHP-knockout mice, FGF19 treatment\",\n      \"journal\": \"Genome biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — ChIP-seq plus functional validation with phospho-mutagenesis and knockout models in single rigorous study\",\n      \"pmids\": [\"26634251\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"FGF19/FGF15 signaling-activated Src phosphorylates hepatic FXR at Y67, which upregulates cholesterol transport genes (Scarb1, Abcg5/8) for biliary cholesterol excretion. Phospho-defective Y67F-FXR substitution blunts cholesterol-lowering, and Src knockdown impairs cholesterol regulation. FGF19 treatment increases FXR occupancy at Abcg5/8 and Scarb1 loci and promotes cholesterol efflux; these effects are abolished by Y67F-FXR or Src inhibition.\",\n      \"method\": \"Hepatic FXR knockout/knockdown reconstitution with Y67F mutant, Src knockdown, apoE-deficient atherosclerosis model, ChIP, cholesterol efflux assay, FGF19 treatment\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — phospho-mutagenesis, Src knockdown, multiple in vivo models, ChIP, functional efflux assays — multiple orthogonal methods\",\n      \"pmids\": [\"30996006\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"FGF19 promotes epithelial-mesenchymal transition (EMT) in HCC cells via the FGFR4/GSK3β/β-catenin axis: FGF19 represses E-cadherin, and EMT induced by FGF19 is blocked by GSK3β inhibitor pretreatment or FGFR4 knockout, implicating GSK3β as a required intermediary.\",\n      \"method\": \"FGF19 overexpression/knockdown, FGFR4 CRISPR knockout, GSK3β inhibitor treatment, EMT marker analysis, invasion assays\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout plus pharmacologic inhibition with defined molecular readouts, single lab\",\n      \"pmids\": [\"26498355\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FGF19 protects HCC cells against endoplasmic reticulum stress-induced apoptosis through the FGFR4-GSK3β-Nrf2 signaling cascade, promoting nuclear accumulation of Nrf2. FGF19 expression in stressed cells is induced by ATF4, which directly binds the FGF19 promoter.\",\n      \"method\": \"ER stress induction in HCC cells, FGF19 overexpression/silencing, mouse xenograft model, signaling pathway analysis\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro mechanistic pathway dissection with in vivo xenograft validation, single lab\",\n      \"pmids\": [\"28951455\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ATF4 (activating transcription factor 4), activated in response to ER stress, directly binds an amino acid response element (AARE) in the FGF19 promoter and induces FGF19 transcription in intestinal cells independently of farnesoid X receptor. Thapsigargin-induced ER stress markedly increases FGF19 mRNA and secreted protein in Caco-2 cells; shRNA depletion of ATF4 attenuates this induction.\",\n      \"method\": \"Reporter gene assay with promoter deletion constructs, EMSA, ChIP assay, ATF4 overexpression/shRNA knockdown\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EMSA and ChIP with functional reporter and shRNA validation, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"23205607\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"FGF19 expression in intestinal cells is induced by lithocholic acid (LCA) via the pregnane X receptor (PXR). PXR/RXR overexpression with LCA or rifampicin stimulation drives FGF19 promoter activity, and the LCA-responsive element maps to a proximal region with two PXR binding half-sites.\",\n      \"method\": \"Reporter gene assay with FGF19 promoter deletion constructs, PXR/RXR co-transfection, qRT-PCR in LS174T intestinal cells\",\n      \"journal\": \"World journal of gastroenterology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter deletion mapping with PXR co-transfection, single lab, multiple constructs\",\n      \"pmids\": [\"17696253\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"FXR transcriptionally activates FGF19 through multiple responsive elements in the FGF19 promoter and gene body (at -1866 to -1833, -1427 to -1353, and -75 to +262 relative to the transcription start), where FXR/RXRα heterodimers bind IR1, ER2, and DR8 motifs as confirmed by EMSA and ChIP assay.\",\n      \"method\": \"Reporter assay with multiple FGF19 promoter deletion constructs, EMSA, ChIP assay, mutagenesis of nuclear receptor binding motifs\",\n      \"journal\": \"The Journal of steroid biochemistry and molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EMSA, ChIP and functional mutagenesis, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"22561792\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"SREBP-2 negatively regulates FXR-dependent transcription of FGF19 in human intestinal cells by interacting directly with FXR and attenuating FXR/RXRα binding to the IR-1 motif in the FGF19 gene, without itself binding the IR-1 motif. GST pull-down confirmed direct SREBP-2/FXR protein interaction.\",\n      \"method\": \"Reporter gene assay, EMSA, ChIP assay, GST pull-down, overexpression of constitutively active SREBP-2, site mutagenesis\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — GST pull-down plus ChIP and reporter assays, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"24321096\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"FOXC1 transcription factor directly regulates FGF19 expression in corneal and periocular mesenchymal cells. FGF19 signals through FGFR4 tyrosine kinase to promote MAPK phosphorylation in the cornea. Loss of either FOXC1 or FGF19 causes complementary anterior segment dysgeneses.\",\n      \"method\": \"Chromatin enrichment assay, cell culture overexpression, zebrafish embryo loss-of-function, MAPK phosphorylation assays\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — chromatin binding assay, in vivo zebrafish loss-of-function, signaling readout — single lab\",\n      \"pmids\": [\"17000708\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"In the chick embryo, FGF19 is expressed in the distal optic vesicle and signals through FGFR4 to participate in lens induction in collaboration with FGF8-L-Maf signaling. Inhibition of FGF19 signal via a secreted FGFR4 decoy induces L-Maf expression; L-Maf misexpression ectopically induces Fgf19; FGF8 induces Fgf19 in addition to L-Maf.\",\n      \"method\": \"Misexpression (gain-of-function) and secreted dominant-negative FGFR4 (loss-of-function) in chick embryo, gene expression analysis\",\n      \"journal\": \"Development, growth & differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo gain- and loss-of-function in chick embryo with defined epistatic relationships, single lab\",\n      \"pmids\": [\"15921496\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"In zebrafish, Fgf19 is required for forebrain development: Fgf19 knockdown reduces cell proliferation and survival in the embryonic brain, impairs development of the ventral telencephalon and diencephalon, and disrupts specification of GABAergic interneurons and oligodendrocytes. Fgf19 expression is downstream of Hedgehog (Hh) signaling, and Fgf19 overexpression partially rescues the forebrain phenotype caused by Hh inhibition.\",\n      \"method\": \"Morpholino knockdown of Fgf19 in zebrafish, Hh pathway inhibition, Fgf19 overexpression rescue experiment\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function morpholino and gain-of-function rescue in zebrafish with defined cellular phenotypes, single lab\",\n      \"pmids\": [\"16256099\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"In zebrafish, Fgf19 expressed in the nasal retina and lens is required for lens fiber cell differentiation, cell survival (but not proliferation) in the lens and retina, and nasal-temporal patterning of the retina critical for retinal ganglion cell axon guidance. Loss of Fgf19 causes size reduction of lens and retina, failure of choroid fissure closure, and aberrant axon pathfinding.\",\n      \"method\": \"Morpholino knockdown of Fgf19, Fgf19 overexpression, eye transplantation in zebrafish, marker gene analysis\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function, gain-of-function, and tissue transplantation in zebrafish with defined developmental phenotypes\",\n      \"pmids\": [\"18089288\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"In breast cancer cells co-expressing FGFR4 and FGF19, FGF19 acts as an autocrine ligand that activates FGFR4 to promote survival predominantly via PI3K/AKT signaling. siRNA silencing of FGF19 or neutralizing anti-FGF19 antibody decreases AKT phosphorylation and suppresses cancer cell growth and doxorubicin resistance specifically in FGFR4+/FGF19+ cells.\",\n      \"method\": \"siRNA knockdown, neutralizing antibody, AKT phosphorylation assays, cell viability assays in breast cancer cell lines\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNAi and antibody blockade with defined signaling readouts, single lab\",\n      \"pmids\": [\"27192118\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Molecular elements in the C-terminus of FGF19 are critical for KLB binding and receptor signaling. Short C-terminal FGF19 peptides competitively inhibit FGF19 activity via KLB binding. A single C-terminal amino acid in FGF19 modulates relative activity through FGFR1 versus FGFR4. The C-terminal sequence of FGF19 is structurally conserved for KLB binding despite sequence differences from FGF21.\",\n      \"method\": \"C-terminal peptide competition assays, alanine scanning mutagenesis, in vitro KLB-mediated signaling assays, in vivo obese mouse metabolic studies\",\n      \"journal\": \"Molecular metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — peptide-based structure-function with in vitro and in vivo validation, single lab\",\n      \"pmids\": [\"29789271\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"IL-1β inhibits β-Klotho expression in hepatocytes via the JNK and NF-κB pathways, thereby impairing FGF19-induced ERK1/2 activation and cell proliferation. LPS inhibits β-Klotho and FGFR4 expression in mouse liver in vivo, but acts via IL-1β (not TNFα or IL-6) to inhibit β-Klotho transcription in liver cells.\",\n      \"method\": \"LPS treatment in vivo, cytokine treatment of hepatocyte cell lines, pathway inhibitors (JNK, NF-κB), FGF19 signaling readout (ERK1/2 phosphorylation), cell proliferation assay\",\n      \"journal\": \"American journal of physiology. Endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo and in vitro complementary approaches with defined signaling readouts, single lab\",\n      \"pmids\": [\"26670488\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"FGF19 promotes HDL biogenesis and transhepatic cholesterol efflux by selectively modulating LXR signaling in the liver; ABCA1 and FGFR4 are identified as mediators. A constitutively active MEK1 (but not constitutively active STAT3) mimics FGF19/NGM282 effects on cholesterol, placing MEK1 downstream of FGF19 in cholesterol regulation.\",\n      \"method\": \"In vivo treatment of db/db and Apoe-/- mice, constitutively active MEK1/STAT3 constructs, ABCA1 and FGFR4 perturbation, cholesterol efflux assays, clinical trial measurement of HDL-C\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo mechanistic pathway dissection with constitutively active constructs and clinical corroboration, single lab\",\n      \"pmids\": [\"30679232\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"FGF19/FGFR4 signaling promotes liver cancer stem cell (LCSC) self-renewal via activation of store-operated Ca2+ entry (SOCE) through both the PLCγ and ERK1/2 pathways. SOCE-calcineurin signaling then activates and induces nuclear translocation of NFATc2, which transcriptionally activates stemness genes (NANOG, OCT4, SOX2) as well as FGF19 itself, creating a positive feedback loop.\",\n      \"method\": \"FGF19 overexpression/silencing, FGFR4 activation/inhibition, Ca2+ imaging, sphere formation and clonogenicity assays, loss-of-function studies\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple gain/loss-of-function approaches with defined Ca2+ signaling readouts, single lab\",\n      \"pmids\": [\"33754043\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"FGF19/FGFR4 signaling elevates ETV4 expression through ERK1/2 in HCC cells; ETV4 in turn upregulates FGFR4, creating a positive feedback loop. ETV4 transactivates PD-L1 and CCL2, promoting TAM and MDSC infiltration and suppressing CD8+ T cells to facilitate HCC metastasis. CCR2 inhibition or CCL2 knockdown impairs ETV4-induced immune cell infiltration.\",\n      \"method\": \"Orthotopic HCC mouse models, lentiviral overexpression/knockdown, flow cytometry, immunofluorescence, clodronate liposome macrophage depletion, CCR2 inhibitor treatment\",\n      \"journal\": \"Journal of hepatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple in vivo models with immune cell phenotyping and pathway validation, single lab\",\n      \"pmids\": [\"36907560\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"In colorectal cancer liver metastasis (CRLM), FGF19 induces polarization of hepatic stellate cells to inflammatory cancer-associated fibroblasts (iCAFs) by activating the FGFR4-JAK2-STAT3 pathway and an autocrine IL-1α loop. FGF19-induced iCAFs promote neutrophil extracellular trap (NET) formation via complement C5a and IL-1β, facilitating CRC liver colonization.\",\n      \"method\": \"In vivo liver metastasis models, FGFR4 pathway inhibition (fisogatinib), GPBAR1 knockout mice, GBC cell line experiments\",\n      \"journal\": \"Advanced science (Weinheim, Baden-Wurttemberg, Germany)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo metastasis model with mechanistic pathway dissection, single lab\",\n      \"pmids\": [\"37345586\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"In gallbladder carcinoma, bile acids upregulate FGF19 and FGFR4 co-expression by activating the GPBAR1-cAMP-EGR1 pathway. FGF19 secreted from GBC cells promotes GBC progression via autocrine FGFR4 activation and downstream ERK signaling.\",\n      \"method\": \"GBC cell line experiments, GPBAR1 knockout mice, human patient samples (serum/bile), FGFR4 inhibitor treatment, transcription factor analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — complementary in vitro, in vivo, and human subject evidence for a defined signaling pathway, single lab\",\n      \"pmids\": [\"34163030\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"HMGA1 chromatin regulator directly induces FGF19 expression by recruiting active histone marks (H3K4me3, H3K27Ac) to the FGF19 gene locus. FGF19 disruption (gene silencing or FGFR4 inhibitor BLU9931) recapitulates most phenotypes of HMGA1 deficiency — decreased tumor growth and desmoplastic stroma formation — in PDAC mouse models.\",\n      \"method\": \"RNA sequencing, ChIP for active histone marks, FGF19 gene silencing, FGFR4 inhibitor treatment, KPC mouse model, subcutaneous/orthotopic PDAC models\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-based epigenetic mechanism with multiple in vivo loss-of-function validation models, single lab\",\n      \"pmids\": [\"36919699\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"The anti-obesity effect of FGF19 in mice does not require UCP1-dependent thermogenesis; FGF19-induced weight loss in UCP1 knockout mice is associated with inhibition of bile acid synthesis and reduction of dietary lipid absorption (increased fecal energy content, reduced hepatic bile acid species), rather than increased caloric expenditure.\",\n      \"method\": \"UCP1 knockout mice, FGF19 treatment, calorimetry, bile acid analysis, fecal energy content measurement, gene expression\",\n      \"journal\": \"Molecular metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout with pharmacologic treatment and multiple metabolic readouts, single lab\",\n      \"pmids\": [\"31767164\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FGF19 is an ileum-derived postprandial endocrine hormone that acts as a ligand for receptor complexes comprising FGFR4 (primarily in liver) or FGFR1-3 (in adipose and other tissues) together with the obligate co-receptor β-Klotho (KLB); upon hepatic FGFR4/KLB activation it suppresses CYP7A1-mediated bile acid synthesis, stimulates insulin-independent glycogen and protein synthesis via a MAPK pathway, represses hepatic autophagy through an FGF19-SHP-LSD1 epigenetic axis, promotes cholesterol efflux via ABCA1/LXR/MEK1 signaling, and phosphorylates FXR at Y67 via Src to reinforce bile acid homeostasis; its mitogenic/oncogenic activity (hepatocellular carcinoma) is mediated separately through FGFR4-STAT3 activation driven non-cell-autonomously by IL-6 from the liver microenvironment, while its pharmacologic weight-loss and glycemic effects require neuronal β-Klotho independently of liver or adipose actions.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"FGF19 is an intestine-derived endocrine hormone that coordinates postprandial hepatic metabolism by acting as a ligand for FGF receptors in partnership with the obligate co-receptor \\u03b2-Klotho (KLB), with tissue-specific outputs dictated by which FGFR isoform is co-expressed with KLB [#0, #1]. Signaling efficiently through FGFR4-KLB in liver and through FGFR1c/2c/3c-KLB in extrahepatic tissues, FGF19 partitions its activities along structurally separable receptor-binding determinants: residues governing FGFR4 engagement drive bile acid suppression and hepatocyte proliferation, while distinct determinants mediate FGFR1c-dependent metabolic regulation of glucose and lipid homeostasis [#2, #3, #4, #9]. Through hepatic FGFR4 it represses CYP7A1-mediated bile acid synthesis [#1], and it stimulates insulin-independent glycogen and protein synthesis via a MAPK pathway that activates glycogen synthase and the translation machinery [#5]. FGF19 reinforces bile acid and cholesterol homeostasis by activating Src to phosphorylate FXR at Y67, controlling FXR nuclear localization and its transcription of cholesterol-transport genes [#13, #16], and it directs cholesterol handling through SHP\\u2014both as a phospho-dependent SREBP-2 partner suppressing cholesterol biosynthesis [#15] and through an LXR/ABCA1/MEK1 axis promoting HDL biogenesis and cholesterol efflux [#30]. FGF19 also enforces postprandial epigenetic repression of hepatic autophagy via an FGF19-SHP-LSD1 axis that demethylates H3K4 at autophagy gene promoters [#14]. Its pharmacologic weight-loss and glycemic effects are mediated through neuronal \\u03b2-Klotho rather than liver or adipose tissue [#12], and anti-obesity action is independent of UCP1 thermogenesis, reflecting reduced bile acid synthesis and dietary lipid absorption [#36]. Distinct from its metabolic roles, FGF19 is oncogenic in hepatocellular carcinoma through FGFR4-driven STAT3 activation that operates non-cell-autonomously via IL-6 from the liver microenvironment, an activity separable from bile acid regulation [#10, #11]. FGF19 transcription is induced in the intestine by bile acid/nuclear-receptor inputs (FXR, PXR) and by ER stress via ATF4 [#19, #20, #21], and it functions developmentally through FGFR4-MAPK signaling in eye and forebrain morphogenesis [#23, #24, #25, #26].\",\n  \"teleology\": [\n    {\n      \"year\": 2007,\n      \"claim\": \"Established the receptor logic of FGF19 by showing that \\u03b2-Klotho is the obligate co-receptor that licenses FGF19 binding and signaling, explaining how a circulating hormone achieves tissue-specific action.\",\n      \"evidence\": \"Cell-based signaling, receptor binding, and in vivo mouse injection with tissue-specific c-Fos/CYP7A1 readouts\",\n      \"pmids\": [\"17623664\", \"17627937\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of the FGF19-KLB-FGFR4 ternary complex not resolved\", \"Determinants of FGFR isoform selectivity not yet mapped\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Dissected which receptor drives which output, showing FGFR4 engagement is responsible for bile acid suppression and hepatocyte proliferation while \\u03b2-Klotho/FGFR1c mediates glucose regulation.\",\n      \"evidence\": \"C-terminal deletion mutant (FGF19dCTD), chimeric FGF19/FGF21 proteins, in vivo treatment in ob/ob mice with gene expression and proliferation readouts\",\n      \"pmids\": [\"19706524\", \"20018895\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether adipose versus other extrahepatic FGFR1c tissues carry the glucose effect not pinned down at this stage\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Confirmed that mitogenic FGFR4 activity and metabolic activity are structurally separable, enabling design of non-mitogenic metabolic variants.\",\n      \"evidence\": \"Structure-guided mutagenesis with in vivo metabolic and proliferation assays in mice\",\n      \"pmids\": [\"20660733\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Long-term safety of FGFR4-sparing variants not addressed\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Defined how FGF19 maintains postprandial fuel homeostasis, showing it drives glycogen and protein synthesis via MAPK independently of insulin/Akt.\",\n      \"evidence\": \"In vivo isotope labeling, pathway inhibitors, FGF15-null mice, and streptozotocin-diabetic rescue\",\n      \"pmids\": [\"21436455\", \"21437243\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor and effector linking MAPK to glycogen synthase not fully defined\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identified upstream transcriptional control of FGF19 by bile acids and xenobiotic sensing, including a pathological PXR-driven program in colon cancer.\",\n      \"evidence\": \"ChIP for PXR on FGF19 promoter, xenograft rescue, RNAi, and reporter assays; PXR/RXR LCA-responsive promoter mapping\",\n      \"pmids\": [\"21747170\", \"17696253\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab xenograft evidence\", \"Relevance of tumor-specific FGF19 induction to human colon cancer not established\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Quantified FGF19 versus FGF21 receptor preferences and engineered biased variants, confirming the \\u03b2Klotho/FGFR1c complex is central to metabolic action.\",\n      \"evidence\": \"Quantitative binding kinetics, signaling assays, and in vivo metabolic phenotyping of FGF19-7 variant in DIO/ob/ob mice\",\n      \"pmids\": [\"22442730\", \"22457778\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab biased-variant data\", \"Affinity measurements not tied to in-tissue receptor stoichiometry\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Mapped the intestinal FXR-driven transcriptional activation of FGF19 and its negative regulation, defining feedback control of the bile acid circuit.\",\n      \"evidence\": \"Reporter assays, EMSA, ChIP, GST pull-down, and SREBP-2 overexpression in human intestinal cells\",\n      \"pmids\": [\"22561792\", \"24321096\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo relevance of SREBP-2/FXR antagonism not tested\", \"Single-lab promoter work\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Linked ER stress to FGF19 induction via ATF4 binding an amino acid response element in the promoter, independent of FXR.\",\n      \"evidence\": \"Reporter deletion constructs, EMSA, ChIP, and ATF4 overexpression/shRNA in Caco-2 cells\",\n      \"pmids\": [\"23205607\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological/pathological context of stress-induced FGF19 not defined in vivo\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Separated FGF19's oncogenic activity from its metabolic activity by showing HCC promotion proceeds through STAT3, an activity removable in the M70 variant.\",\n      \"evidence\": \"Engineered M70 variant, transgenic HCC mouse model, and STAT3 signaling/tumor growth assays\",\n      \"pmids\": [\"24728076\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism connecting FGFR4 to STAT3 not resolved at this stage\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified SHP as a phospho-dependent SREBP-2 partner downstream of FGF19 that represses cholesterol biosynthesis genes genome-wide.\",\n      \"evidence\": \"Liver ChIP-seq, Co-IP, SHP Thr-55 phospho-mutagenesis, and SHP-knockout mice with FGF19 treatment\",\n      \"pmids\": [\"26634251\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinase phosphorylating SHP at Thr-55 not identified\", \"Single rigorous study\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Resolved the non-cell-autonomous basis of FGF19-driven HCC, showing FGF19 stimulates microenvironmental IL-6 that activates hepatocyte STAT3.\",\n      \"evidence\": \"Hepatocyte-specific Stat3 knockout, Il6 knockout, anti-IL-6 antibody, and JAK inhibitor in transgenic HCC mice\",\n      \"pmids\": [\"28508871\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cellular source of IL-6 and the FGF19 receptor on those cells not fully defined\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Localized the pharmacologic weight-loss and glycemic effects of FGF19 to neuronal \\u03b2-Klotho, redefining the relevant target tissue.\",\n      \"evidence\": \"Neuronal, hepatic, and adipose tissue-specific \\u03b2-Klotho knockout mice with metabolic phenotyping\",\n      \"pmids\": [\"28988823\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific neuronal populations and downstream circuits not identified\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Defined a post-translational arm of bile acid homeostasis in which FGF19-activated Src phosphorylates FXR at Y67 to control its nuclear localization, and an epigenetic arm repressing hepatic autophagy via SHP-LSD1.\",\n      \"evidence\": \"Y67F-FXR phospho-mutagenesis, liver-specific viral expression, Src knockdown, bile acid feeding/cholestasis models; SHP-null, LSD1-knockdown, FGF15-null mice with ChIP and autophagy assays\",\n      \"pmids\": [\"29968724\", \"28446510\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How FGF19/FGFR4 signaling activates Src not detailed\", \"Promoter selectivity of the SHP-LSD1 complex incompletely defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Extended FGF19's lipid control to biliary cholesterol excretion (via Y67-phosphorylated FXR at Abcg5/8 and Scarb1) and to HDL biogenesis through an LXR/ABCA1/MEK1 axis.\",\n      \"evidence\": \"Hepatic FXR reconstitution with Y67F mutant, Src knockdown, apoE-/- atherosclerosis model, ChIP, efflux assays; constitutively active MEK1/STAT3 constructs and ABCA1/FGFR4 perturbation in db/db and Apoe-/- mice\",\n      \"pmids\": [\"30996006\", \"30679232\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab studies\", \"Integration of MEK1 and FXR-phosphorylation arms not reconciled\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed FGF19's anti-obesity action does not require UCP1 thermogenesis but reflects suppressed bile acid synthesis and reduced lipid absorption.\",\n      \"evidence\": \"UCP1 knockout mice with FGF19 treatment, calorimetry, bile acid and fecal energy analysis\",\n      \"pmids\": [\"31767164\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Reconciliation with the neuronal \\u03b2-Klotho mechanism not directly addressed\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Expanded the FGF19/FGFR4 oncogenic program across tumor types through autocrine signaling, feedback loops, and immune-stromal remodeling.\",\n      \"evidence\": \"Orthotopic/xenograft HCC, PDAC, gallbladder and colorectal liver metastasis models with pathway inhibitors, knockouts, ChIP, Ca2+ imaging, and immune cell phenotyping\",\n      \"pmids\": [\"33754043\", \"36907560\", \"37345586\", \"34163030\", \"36919699\", \"26498355\", \"28951455\", \"27192118\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Each mechanism rests on single-lab evidence\", \"Relative contribution of these parallel oncogenic arms in human tumors unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the divergent FGF19 outputs\\u2014hepatic metabolic, neuronal pharmacologic, and oncogenic STAT3/immune arms\\u2014are integrated at the level of receptor complex composition and downstream effector choice remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of context-dependent receptor complexes\", \"Mechanism selecting MAPK versus STAT3 versus Src outputs not defined\", \"Branch point between metabolic and oncogenic signaling not mapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 2, 3, 8]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 1, 5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [19]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [5, 15, 30]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 5, 13]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [10, 11]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [14]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"KLB\", \"FGFR4\", \"FGFR1\"]\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}